% | $
Quotes you view appear here for quick access.

Novadaq Technologies Inc. Message Board

gopointers2 2 posts  |  Last Activity: Oct 28, 2015 4:15 PM Member since: Oct 24, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by smarion555 Oct 28, 2015 3:45 PM
    gopointers2 gopointers2 Oct 28, 2015 4:15 PM Flag

    So $17.0M, with a 74% margin and ($0.07) loss per share. Capital sales up 18.5% sequentially. Sounds like a beat to me, so I'd like to say the shorts lose, but you know how this goes... What looks like a sure thing (short squeeze) rarely comes to fruition.

  • Reply to

    Morgan Stanley Presentation

    by e11ndofwar Sep 18, 2015 7:43 AM
    gopointers2 gopointers2 Sep 18, 2015 9:34 AM Flag

    I want to add a couple of notes I took:

    -15% of this year's growth is due to ending the LifeCell agreement, due to the fact there is no 50-50 splitting of revenue. The analyst asked why they felt confident growth will pick up in the second half of 2015 going forward and Arun said they think the LifeCell transition is over and the large number of new salespeople are just becoming productive (this last 1/2 sentence is my paraphrasing of Arun's statement).

    -In 12 to 18 months utilization will be a bigger driver. This will be interesting to see how quickly revenue from kit sales starts to gain on capital sales as Novadaq will eventually be making more revenue off the "razor blades" than the "razors".

    -This fall their introducing a generation of new products and upgrades.

    -Arun mentioned something I've never heard before, that there are 3-4 other companies with approved products that may eventually be competitors. We all new about Stryker, but I'm not really aware about the other companies. He did seem to not be too concerned with them, as Novadaq has a lot of IP for the other companies to overcome here, but we need to get the growth up to keep the first-mover advantage.

12.10+0.01(+0.08%)Nov 27 1:00 PMEST